Amizadeh Maryam, Mozafarnia Keramat, Moslemikia Javad, Naghibzadeh-Tahami Ahmad
Clinical Research Development Unit, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Clinical Research Unit, Jiroft University of Medical Science, Jiroft, Iran.
Iran J Otorhinolaryngol. 2021 Jan;33(114):9-13. doi: 10.22038/ijorl.2020.43887.2452.
Oral prednisolone was suggested as the first step to treat idiopathic sudden sensorineural hearing loss (ISSHL). This study aimed to investigate the effect of pulse therapy with methylprednisolone and intratympanic methylprednisolone, compared to traditional oral prednisolone therapy on patients with ISSHL.
This randomized control trial included an experimental group receiving 500 mg intravenous methylprednisolone for three sequential days, followed by 1 mg/kg oral prednisolone for 11 days, and intratympanic Depo-Medrol four times twice a week. On the other hand, the control group received 1 mg/kg oral prednisolone for 14 days. Hearing change was assessed through pure tone audiometry. Subsequently, hearing recovery was investigated and analyzed in this study.
This study was conducted on 51 patients who were divided into two groups of experimental (n=26) and control (n=25). The result revealed no significant difference between the two groups in terms of hearing improvement (P=0.28).
This revealed no added benefit in pulse steroids combined with intratympanic injections in cases with sudden hearing loss.
口服泼尼松龙被建议作为治疗特发性突发性感音神经性听力损失（ISSHL）的第一步。本研究旨在调查与传统口服泼尼松龙疗法相比，甲泼尼龙脉冲疗法和鼓室内注射甲泼尼龙对ISSHL患者的疗效。
这项随机对照试验包括一个实验组，该组连续三天接受500毫克静脉注射甲泼尼龙，随后11天接受1毫克/千克口服泼尼松龙，并每周两次、共四次鼓室内注射得宝松。另一方面，对照组接受1毫克/千克口服泼尼松龙治疗14天。通过纯音听力测定评估听力变化。随后，在本研究中对听力恢复情况进行调查和分析。
本研究对51例患者进行了分组，分为实验组（n = 26）和对照组（n = 25）。结果显示两组在听力改善方面无显著差异（P = 0.28）。
这表明在突发性听力损失病例中，脉冲类固醇联合鼓室内注射并无额外益处。
